| Literature DB >> 34950641 |
Neelam Mishra1, Kavita Rana2, Siva Deepthi Seelam1, Rakesh Kumar3, Vijyendra Pandey4, Bharathi P Salimath5,6, Dayanand Agsar1.
Abstract
A biosurfactant producing bacterium was identified as Pseudomonas aeruginosa DNM50 based on molecular characterization (NCBI accession no. MK351591). Structural characterization using MALDI-TOF revealed the presence of 12 different congeners of rhamnolipid such as Rha-C8-C8:1, Rha-C10-C8:1, Rha-C10-C10, Rha-C10-C12:1, Rha-C16:1, Rha-C16, Rha-C17:1, Rha-Rha-C10:1-C10:1, Rha-Rha-C10-C12, Rha-Rha-C10-C8, Rha-Rha-C10-C8:1, and Rha-Rha-C8-C8. The radical scavenging activity of rhamnolipid (DNM50RL) was determined by 2, 3-diphenyl-1-picrylhydrazyl (DPPH) assay which showed an IC50 value of 101.8 μg/ ml. The cytotoxic activity was investigated against MDA-MB-231 breast cancer cell line by MTT (4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide) assay which showed a very low IC50 of 0.05 μg/ ml at 72 h of treatment. Further, its activity was confirmed by resazurin and trypan blue assay with IC50 values of 0.01 μg/ml and 0.64 μg/ ml at 72 h of treatment, respectively. Thus, the DNM50RL would play a vital role in the treatment of breast cancer targeting inhibition of p38MAPK.Entities:
Keywords: MDA-MB-231 cell lines; MTT; TNBC; cytotoxic; p38MAPK; resazurin; rhamnolipid; trypan blue
Year: 2021 PMID: 34950641 PMCID: PMC8691732 DOI: 10.3389/fbioe.2021.761266
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Phylogenetic tree of the isolate DNM50.
FIGURE 2Chemical characterization of Rhamnolipid (DNM50RL) produced from Pseudomonas aeruginosa DNM50 by (A) thin-layer chromatography (TLC): TLC plate run in a solvent system of butanol:acetic acid:water (2:1:1), developed with Molisch reagent (α—naphthol in ethanol and H2SO4) showing typical brown color spots of Rhamnolipid. (B) MALDI TOF peaks.
Molecular ions observed in MALDI-TOF for Rhamnolipids produced by Pseudomonas aeruginosa DNM50.
| Rhamnolipids | Molecular formula | Calcd mass units [M] | [M + Na]+ | [M + K]+ | [M—H +2Na]+ | Observed | |||
|---|---|---|---|---|---|---|---|---|---|
| Obsd | Calcd | Obsd | Calcd | Obsd | Calcd | ||||
| Rha-C8-C8:1 | C22H38O9 | 446.2 | 469 | 469.2 | 483-2H | 485.2 | − | 491.2 | |
| Rha-C10-C8:1 | C24H42O9 | 474.2 | − | 497.2 | 513 | 513.2 | 519 | 519.2 | |
| Rha-C10-C10 | C26H48O9 | 504.3 | 527 | 527.3 | − | 543.2 | − | 549.3 | |
| Rha-C10-C12:1 | C28H50O9 | 530.3 | 553 | 555.3 | 569 | 569.3 | − | 575.3 | |
| Rha-C16:1 | C22H38O7 | 414.2 | − | 437.2 | − | 453.2 | − | 459.2 | 414 |
| Rha-C16 | C22H40O7 | 416.2 | − | 439.2 | 456 + H | 455.2 | − | 461.2 | |
| Rha-C17:1 | C23H40O7 | 428.2 | − | 451.2 | − | 467.2 | − | 473.2 | 425 |
| Rha-Rha-C10:1-C10:1 | C32H54O13 | 646.3 | − | 669.3 | 685 | 685.3 | − | 691.3 | |
| Rha-Rha-C10-C12 | C34H62O13 | 678.4 | 701 | 701.4 | − | 717.3 | − | 723.4 | |
| Rha-Rha-C10-C8 | C30H54O13 | 622.3 | 644-H | 645.3 | − | 661.3 | − | 667.3 | |
| Rha-Rha-C10-C8:1 | C30H52O13 | 620.3 | − | 643.3 | 658 -H | 659.3 | − | 665.3 | |
| Rha-Rha-C8-C8 | C28H50O13 | 594.3 | − | 617.3 | 630-3H | 633.2 | − | 639.2 | 597—3H |
FIGURE 3The DPPH radical scavenging activity of DNM50RL and ascorbic acid (A) Scavenging %. Values represented as mean ± SD of three independent experiments. Error bars represent SD (*p < 0.05). (B) Non-linear regression curve fit (DPPH assay). IC50 determined by nonlinear regression (curve fit [Inhibitor] vs. normalized response–Variable slope) using GraphPad prism software.
FIGURE 4Antiproliferative effect of DNM50RL on MDA-MB 231 cell line by MTT assay after 24, 48, and 72 h of treatment. (A) Dose dependent inhibition. Values represented as mean ± SD of three independent experiments. Error bars represent SD (*p < 0.05). (B) IC50 determination by nonlinear regression [curve fit (Inhibitor) vs. normalized response–Variable slope] using GraphPad prism software.
FIGURE 5Antiproliferative effect of DNM50RL on human breast cancer cell lines MDA-MB- 231 cell line by resazurin assay after 24, 48, and 72 h of treatment. (A) Dose dependent inhibition. Values represented as mean ± SD of three independent experiments. Error bars represent SD (*p < 0.05). (B) IC50 determined by nonlinear regression [curve fit (Inhibitor) vs. normalized response–Variable slope] using GraphPad prism software.
FIGURE 6Cell viability efficacy of DNM50RL on human breast cancer cell lines MDA-MB-231 cell line by trypan blue assay after 24, 48, and 72 h of treatment. (A) Dose dependent inhibition. Values represented as mean ± SD of three independent experiments. Error bars represent SD (*p < 0.05). (B) IC50 determined by nonlinear regression [curve fit (Inhibitor) vs. normalized response–Variable slope] using GraphPad prism software.
IC50 values of few glycolipid based biosurfactants against different cell lines.
| Biosurfactant | Source | Cell line | Cytotoxic assay | IC50/LC50/GI50/EC50 | Treatment time | References |
|---|---|---|---|---|---|---|
| Rhamnolipid 1; Rhamnolipid 2 |
| HepG2 liver cancer cell line; A549 lung cancer cell line; MDA-MB-231 cell line; HeLa cell line | MTT assay | 140 μM, 154 μM, 86 μM, 123 µM; 79 μM, 98 μM, 58 μM, 88 µM | 48 h |
|
| Glycolipid biosurfactant S9BS |
| HEK-293, a human embryonic kidney cancer cell | MTT assay | 75 μg/ ml (LC50) | 24 h |
|
| Monorhamnolipid (NDYS-4E) |
| MCF-7, a breast cancer cell line | MTT assay | 88.60 μg/ ml | 48 h |
|
| BS1a; BS1b | R—95TM RL; R—90 TM RL | MCF—7, a breast cancer cell line | MTT assay | 153.40 μg/ ml,98.27 μg/ ml,33.08 μg/ ml; 168.50 μg/ ml, 42.85 μg/ ml,30.05 μg/ ml | 24 h, 48 h, 72 h |
|
| Rhizoleucinoside, a RL - amino-alcohol hybrid |
| Murine microglia; Rat microglia | CellTiter-Glo 2.0 (CTG 2.0) assay | 6.9 µM; 22 µM | 24 h |
|
| Biosurfactant |
| HEp-2 cell line | MTT assay | 109.1 ± 0.84 mg/ ml to 129.7 ± 0.52 mg/ ml | 48 h |
|
| Dokdolipids A, B, C |
| MDA-MB-231 breast cancer cell line | Sulforhodamine (SRB) assay | 30.6, 40.4, 25.5 µM (GI50) | 48 h |
|
| Monorhamnolipids; Dirhamnolipids |
| MCF-7 breast cancer cell line | MTT assay | 25.87 μg/ ml; 31 μg/ ml | 48 h |
|
| L-SL (Lactonic form of sophorolipids); |
| Human lung adenocarcinoma epithelial cell line A549; | MTT assay | 50 μg/ ml, 40 μg/ ml, 880 μg/ ml, 400 μg/ ml; | 24 h, 48 h |
|
| Glucolipids |
| MDA-MB-231 breast cancer cell line; | 50 μg/ ml, 40 μg/ ml, 900 μg/ ml, 400 μg/ ml; | |||
| 40 μg/ml, 35 μg/ml, 600 μg/ml, 100 μg/ml | ||||||
| MCTG107b (mixture of rhamnolipid analogues); MCTG214 (3b1) (dirhamnolipids congeners) |
| Mouse skin melanoma cell line B16F10 HaCat keratinocyte cell Line THLE3 liver cell line | Almar blue assay | 1.3 ± 0.4 mg/ ml, 0.73 ± 0.1 mg/ ml, 0.76 ± 0.1 mg/ ml (EC50); | 24, 48, 72 h |
|
| 1.28 mg/ ml±0.2, 1.04 ± 0.1 mg/ ml, 0.96 ± 0.1 mg/ ml (EC50); | ||||||
| 1.35 ± 0.1 mg/ ml, 0.78 ± 0.1 mg/ ml, 0.55 ± 0.1 mg/ml (EC50); | ||||||
| 2.3 ± 0.2 mg/ml, 0.99 ± 0.1 mg/ml, 0.84 ± 0.1 mg/ ml (EC50); | ||||||
| RL1; RL2 |
| MCF-7, breast cancer cell line; | MTT assay | 8.68 μg/ ml, 8.67 μg/ ml; | 48 h |
|
| MDA-MB-231 breast cancer cell lines | 6.99 μg/ ml, 8.60 μg/ ml | |||||
| DNM50RL (a mixture of mono and dirhamnolipids) |
| MDA-MB-231 breast cancer cell line | MTT assay Resazurin assay Trypan blue assay | 0.27 μg/ ml.,0.17 μg/ ml,0.05 μg/ ml | 24, 48, 72 h | Present study |
| 1.25 μg/ ml, 1.52 μg/ ml, 0.01 μg/ ml | ||||||
| 0.13 μg/ ml,0.22 μg/ ml,0.64 μg/ ml | ||||||
| Etoposide | Standard anticancer drug | MDA-MB-231 cell line | MTT assay, Resazurin assay Trypan blue assay | 46.59, 25.22, 20.65 µM | 24h, 48h, 72 h | Present study |
| 88.32, 60.94, 25.77 µM | ||||||
| 70.25, 56.01, 51.10 µM |
FIGURE 7(A) Western blot for antibody phosphorylated p38 and total p38. β actin served as loading control. (B) Graph representing the ratio of phosphorylated p38 (p-p38)/total p38 (t-p38). The intensity related to expression of p-p38 and t-p38 was analyzed using ImageJ software. All the results are presented as the means ± SD of three independent measurements. Error bars represent standard deviation. (*) Differences were considered significant at p < 0.05 as compared with control groups.